EditorialBeth Faiman, PhD, MSN, APRN-BC, AOCN®, FAANThis past October, over 1,000 nurse practitioners, PAs, pharmacists, and other oncology professionals attended the ninth annual JADPRO Live conference, which was held virtually from October 7 to 17. The conference featured educational sessions, networking opportunities, and poster presentations t...
Read More
Meeting ReportR. Donald Harvey,(1) PharmD, BCOP, FCCP, FHOPA, Aaron Begue,(2) MS, RN, NP-C, Caleb Raine,(1) PA-C, and Robin Yabroff,(3) PhD, MBAThe COVID-19 pandemic may have changed some aspects of health care forever. At JADPRO Live Virtual 2021, a panel discussion focused on how several cancer centers faced challenges, and what changes the participants view as positive. JADPRO Live is an annual educational conference for advanced prac...
Read More
Meeting Reportby Maimah Karmo,(1) and Amy Pierre,(2),(3) MSN, ANP-BCAs an immigrant from Liberia, Maimah Karmo has experienced disparities firsthand. Today, the CEO and Founder of Tigerlily Foundation is a leader in the field of women’s health—and a breast cancer survivor. By working with members of Congress, Ms. Karmo has created and implemented national health ...
Read More
Meeting ReportElisabeth King,(1) FNP-C, and Sara Toth,(2) FNP-CAchieving a goal may look like sunshine and rainbows from afar, but the leadership journey is rarely a smooth and unbroken path towards success. During JADPRO Live Virtual 2021, Elisabeth King, FNP-C, Executive Director of Genomics and Precision Medicine, City of Hope, and Sara Toth, FNP-C, Direc...
Read More
Meeting ReportMargaret Leddy, PA-C, MMScAn estimated one third of oncology providers had burnout prior to COVID-19. Unfortunately, these percentages have risen substantially since the start of the pandemic. During JADPRO Live Virtual 2021, Margaret Leddy, PA-C, MMSc, physician assistant and Duke Wellness Ambassador, defined burnout in ...
Read More
Meeting ReportBrianna Hoffner,(1) MSN, ANP-BC, AOCNP®, Josh Epworth,(2) ARNP, Beth Faiman,(3) PhD, MSN, APRN-BC, AOCN®, FAAN, and Soumya J. Niranjan,(4) BPharm, MS, PhDIn the spring of 2021, the Association of Community Cancer Centers (ACCC), Harborside, and collaborative partner Pfizer Oncology hosted a 3-day virtual summit to define the role of oncology advanced practitioners (APs) in equitable cancer care delivery. During JADPRO Live Virtual 2021, Brianna Ho...
Read More
Meeting ReportColleen Lewis, MSN, ANP-BC, AOCNP®Although enrollment has increased slightly in recent years, it is estimated that only 8% of patients with cancer in the United States enroll in a clinical trial (Hillyer et al., 2020). According to Colleen Lewis, MSN, ANP-BC, AOCNP®, Director of Clinical Operations, Phase I Program, Winship Cance...
Read More
Meeting ReportRose DiMarco,(1) PharmD, BCPS, BCOP, and Lisania Milli,(2) MSN, RN, WHNP-BCAdvancements in the fight against cancer have not equitably benefitted all population groups. Between 1991 and 2016, the overall cancer death rate declined by 27%, yet socioeconomic disparities in cancer mortality widened, with the most striking disparities observed in cancers most amenable to pr...
Read More
Meeting ReportJoan Okasako,(1) MSN, FNP-BC, RN, AOCNP®, and Carolyn Bernstein,(2) MSN, FNP-BC, RNDiscussion of cancer cases in a multidisciplinary setting goes back more than a century, but in recent decades, multidisciplinary tumors boards (MTBs) have taken on a greater role in cancer care as the field grows in complexity. During JADPRO Live Virtual 2021, Joan Okasako, MSN, FNP-BC, RN, AOCN...
Read More
Meeting ReportDavid DeRemer, PharmD, BCOP, FCCP, FHOPARecognizing clinically relevant drug interactions—drug-drug, drug-food, and drug-herbal—remains an important challenge for advanced practitioners. At JADPRO Live Virtual 2021, David DeRemer, PharmD, BCOP, FCCP, FHOPA, discussed the pharmacodynamic and pharmacokinetic mechanisms of drug interactio...
Read More
Meeting ReportAnecita P. Fadol, PhD, FNP-BC, FAANP, FAANThe growing awareness that many anticancer agents can be cardiotoxic to patients has led to a subspecialty field now known as cardio-oncology. As part of the interdisciplinary oncology team, advanced practitioners play a critical role in identifying, monitoring, and managing the cardiac complicat...
Read More
Meeting ReportLisa W. Goldstone, MS, PharmD, BCPS, BCPPPatients with comorbid mental health and substance use disorders are at greater risk for mortality and have higher cancer care costs. During JADPRO Live Virtual 2021, Lisa W. Goldstone, MS, PharmD, BCPS, BCPP, of the University of Southern California School of Pharmacy, discussed the need for rou...
Read More
Meeting ReportCarrie Peterson, DNP, RN, AGNP-cAlthough rare, infusion-related reactions to immunotherapy can lead to longer infusion times, medical interventions, hospitalizations, treatment discontinuations, and even death. According to Carrie Peterson, DNP, RN, AGNP-c, knowing how these medications work and how the body responds to these m...
Read More
Meeting ReportMailey L. Wilks, DNP, APRN, NP-CCancer significantly increases the risk of developing venous thromboembolism (VTE), which is the second leading cause of death in people with cancer. During JADPRO Live Virtual 2021, Mailey L. Wilks, DNP, APRN, NP-C, of the Cleveland Clinic, reviewed the currently available anticoagulants, includ...
Read More
Meeting ReportCarrie Tompkins Stricker, PhD, RN, ANP-BCWith a growing population of more than 17 million cancer survivors in the United States, survivorship care is more important than ever. During JADPRO Live Virtual 2021, Carrie Tompkins Stricker, PhD, RN, ANP-BC, of Thomas Jefferson University, in Pennsylvania, described the evolving demographic, ...
Read More
Meeting ReportRoberta Bourgon, NDThe practice of naturopathic medicine is growing rapidly in the United States, with 23 states currently licensing naturopathic physicians from six approved schools in the United States. During JADPRO Live Virtual 2021, Roberta Bourgon, ND, a naturopathic physician at Billings Clinic in Montana, d...
Read More
Meeting ReportCara Fleming, AGPCNP-BC, AOCNP®, and Deirdre Kelly, AGACNP-BCDuring JADPRO Live Virtual 2021, Cara Fleming, AGPCNP-BC, AOCNP®, and Deirdre Kelly, AGACNP-BC, of Memorial Sloan Kettering Cancer Center, discussed the metrics, logistics, and workflow used when establishing a successful advanced practitioner (AP)-led oncology urgent care clinic (OUCC). The pres...
Read More
Meeting ReportPaul Wischmeyer, MD, EDIC, FCCM, FASPENApproximately 2 out of 3 patients with gastrointestinal cancer are malnourished at the time of surgery, but only 1 out of 5 patients receives any preoperative nutrition intervention. According to Paul Wischmeyer, MD, EDIC, FCCM, FASPEN, Professor of Anesthesiology and Surgery, Associate Vice Chai...
Read More
Meeting ReportChristine Cambareri, PharmD, BCPS, BCOP, CSPBetween October 2020 and September 2021, there were 32 drug approvals in solid tumor oncology, including 23 regular approvals and 9 accelerated approvals. During JADPRO Live Virtual 2021, Christine Cambareri, PharmD, BCPS, BCOP, CSP, of the University of Pennsylvania Abramson Cancer Center, revie...
Read More
Meeting ReportKirollos Hanna, PharmD, BCPS, BCOPWith multiple new approvals and new indications, 2021 was the year of CAR T-cell therapies in hematologic malignancies. Joining the list of approvals were PI3K inhibitors, anti-CD38 monoclonal antibodies, and expanded indications for immunotherapy.
During JADPRO Live Virtual 2021, Kirollos Hanna...
Read More
Meeting ReportDonald C. Moore, PharmD, BCPS, BCOP, DPLAInvestigators are currently evaluating many new agents in the hematology/oncology pipeline, including novel immunotherapies that can potentially complement existing immunotherapies. Emerging therapeutics are also being evaluated in very difficult-to-treat patient populations, such as TP53-mutant ...
Read More
Meeting ReportPresented by Sandra E. Kurtin,(1) PhD, ANP-C, AOCN®, Alyssa Henglefelt,(2) PharmD, BCOP, and Haleigh Mistry,(3) MS, PA-CBiomarker expression is playing an increasingly important role with the continued approval of a growing number of targeted therapies. In a session called “Biomarker Jeopardy” during JADPRO Live Virtual 2021, Alyssa Henglefelt, PharmD, BCOP, HonorHealth – Virginia G. Piper Cancer Care Network, and...
Read More
Meeting ReportSara M. Tolaney, MD, MPH, and Lindsay Shaw, ANP-BC, AOCNP®Checkpoint inhibitors as monotherapy have demonstrated limited activity in metastatic triple-negative breast cancer, but when given in combination with chemotherapy, significant improvements in disease control and survival have been made. During JADPRO Live Virtual 2021, Sara M. Tolaney, MD, MPH,...
Read More
Meeting ReportBeth Sandy,(1) MSN, CRNP, and Jennifer Morrissette,(2) PhD, FACMGThere are currently nine actionable biomarkers in non–small cell lung cancer (NSCLC), and the list of targeted therapies continues to grow. During JADPRO Live Virtual 2021, Beth Sandy, MSN, CRNP, and Jennifer Morrissette, PhD, FACMG, reviewed the importance of molecular testing in NSCLC and descr...
Read More
Meeting ReportJennifer Jacky,(1) MSN, ARNP, AOCNP®, Kristin DeGroot,(2) PA-C, and Rebecca Denney,(2) PA-CIn 2021, approximately 235,760 Americans were diagnosed with lung cancer, which remains the leading cause of cancer-related deaths in the United States. In fact, last year, more than three times as many Americans lost their lives to lung cancer (155,870) than colorectal cancer (50,260), which is ...
Read More
Meeting ReportPelin Cinar, MD, MS, and Patricia Zendejas, MSN, ANP-C, AOCNP®An aggressive disease with a high mortality rate, the 5-year relative survival of pancreatic cancer remains a dismal 10.8%. A multidisciplinary approach with supportive oncology and palliative care expertise continues to offer the best chance for successful care.
During JADPRO Live Virtual 2021,...
Read More
Meeting ReportKirollos S. Hanna,(1) PharmD, BCPS, BCOP, and Zita D. Lim,(2) PA-CThe most common kidney cancer, renal cell carcinoma is diagnosed in over 300,000 patients worldwide each year, including 74,000 patients in the US. Despite therapeutic advances, 5-year survival is still less than 12% for patients with metastatic disease.
During JADPRO Live Virtual 2021, Kirollos...
Read More
Meeting ReportKristen O’Hagan, MSN, RN, ANP-BC, AOCNP®A rare and deadly cancer, the incidence of cholangiocarcinoma is on the rise, and prognosis remains dismal. For patients with resectable disease, the 5-year survival rate is between 15% to 25%, and for those with metastatic disease, the survival drops to only 2% at 5 years. The recent approvals o...
Read More
Meeting ReportLaura J. Zitella, MS, RN, ACNP-BC, AOCN® As molecular testing technologies are increasingly integrated into clinical research and patient care, they have become essential tools for the treatment of hematologic malignancies. According to Laura J. Zitella, MS, RN, ACNP-BC, AOCN®, nurse practitioner and Associate Clinical Professor at the ...
Read More
Meeting ReportAlli McClanahan, APRN, and Megan Spychalla, PA-C The second most common hematologic malignancy, multiple myeloma remains incurable, with high rates of relapse. Recent advances in combination therapies and new treatment options, however, continue to improve prognosis and survival.
During JADPRO Live Virtual 2021, Alli McClanahan, APRN, and Meg...
Read More
Meeting ReportAshley Leak Bryant,(1) PhD, RN, OCN®, FAAN, and Kaitlyn Buhlinger,(2) PharmD, BCOP, CPPAcute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the US. Recent advances in targeted therapies and low-intensity regimens, however, have resulted in an expansion of treatment options for pa...
Read More
Meeting ReportDavid Hughes, PharmD, BCOPThe treatment of chronic immune thrombocytopenia (cITP) has changed significantly in recent years with the approval of several new drugs, but patient preference still plays an important role in the management of this disease. During JADPRO Live Virtual 2021, David Hughes, PharmD, BCOP, of Boston ...
Read More
Meeting ReportAshley Ames, FNP-BC, and Diane Lee, AGPCNP-BCA number of novel agents have entered the therapeutic arena for diffuse large B-cell lymphoma (DLBCL). Chief among these are antibody-drug conjugates and chimeric antigen therapy (CAR) T-cell therapies. While new treatments are improving survival, the COVID-19 pandemic has added another layer to ...
Read More
Editorial Patricia A. Kelly, DNP, APRN, CNS, AGN-BC, AOCN®, Kathleen Calzone, PhD, RN, AGN-BC, FAAN, Patricia Friend, PhD, APRN-CNS, AOCNS®, AGN-BC, and Suzanne M. Mahon DNS RN AOCN® AGN-BC FAANBeth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN JADPRO, Editor-in-Chief
Dear Dr. Faiman,
We read with interest the April 2022 JADPRO meeting report article, “Molecular Testing in Hematologic Malignancies”, as presented by Laura Zitella, MS, RN, ACNP-BC, AOCN®. We were pleased that Ms. Zitella ...
Read More